title: Trastuzumab beyond progression in retrospective analyses: an issue of equal opportunities.
authors.forename: Filippo
authors.initials: F
authors.lastname: Montemurro
authors.forename: Stefania
authors.initials: S
authors.lastname: Redana
authors.forename: Elena
authors.initials: E
authors.lastname: Geuna
authors.forename: Andrea
authors.initials: A
authors.lastname: Milani
authors.forename: Valentina
authors.initials: V
authors.lastname: Rossi
authors.forename: Rossella
authors.initials: R
authors.lastname: Martinello
authors.forename: Giorgio
authors.initials: G
authors.lastname: Valabrega
authors.forename: Massimo
authors.initials: M
authors.lastname: Aglietta
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000401:mortality; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate; D000068878:Trastuzumab; D016896:Treatment Outcome; D028761:Withholding Treatment
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068878:Trastuzumab